Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Arvinas Q1 2026 Earnings Call - First PROTAC Approved, VEPPANU Licensed to Rigel, Pipeline Advances Amid Cost Cuts
Arvinas delivered a landmark quarter with the FDA approval of VEPPANU, the first-ever PROTAC degrader, and a global licensing deal with Rigel Pharmaceuticals to commercialize the asset. The move allow...
- FDA approved VEPPANU (vepdegestrant), the first-ever PROTAC degrader, for ESR1 mutant, ER+ advanced breast cancer.
- Arvinas licensed global rights to VEPPANU to Rigel Pharmaceuticals, with Pfizer retaining a 50% interest in economics.
- Rigel will commercialize VEPPANU in the U.S. and manage international development, with Arvinas receiving upfront and milestone payments.
- +7 more takeaways
Abeona Therapeutics Q1 2026 Earnings Call - ZEVASKYN Revenue Surges as Company Bets on Novel Prostate Cancer Therapy
Abeona Therapeutics is moving from a rare disease orphan play to a broader cell therapy contender, and the market is watching the pivot closely. The company reported a sharp jump in ZEVASKYN revenue t...
- ZEVASKYN revenue surged 263% quarter-over-quarter to $8.7 million, driven by three commercial patients treated in Q1 2026 compared to just one in Q4 2025.
- The company has activated six Qualified Treatment Centers (QTCs), including NewYork-Presbyterian/Columbia and Children’s Hospital of Philadelphia, and is on track to add a seventh by year-end.
- A growing pipeline of over 100 identified patients across QTCs and community physicians suggests strong demand, with one patient biopsied and manufacturing underway, and six more expected this quarter.
- +9 more takeaways
Acurx Pharmaceuticals Q1 2026 Earnings Call - Ibezapolstat Clears Key Regulatory Hurdles with FDA's One-Trial Standard
Acurx Pharmaceuticals advanced its ibezapolstat program for recurrent C. difficile infection (rCDI) by launching an open-label pilot study targeting multiply recurrent patients, with plans for a phase...
- Acurx launched a 20-patient open-label pilot study for ibezapolstat in multiply recurrent C. difficile infection (rCDI), with first patient dosing expected around August 2026.
- The FDA recently issued final guidance that may allow single-trial approval for CDI, potentially ending the two-trial dogma and accelerating Acurx's path to market.
- Phase II data for ibezapolstat in acute CDI showed a 96% cure rate with zero recurrences in 25 patients, with five remaining recurrence-free at three months.
- +7 more takeaways
Madison Air Q1 2026 Earnings Call - Record Backlog and Data Center Momentum Drive Strong Q1 Performance
Madison Air delivered a robust first quarter as a newly public company, with pro forma net sales up 13% to $924 million and adjusted EBITDA margins expanding 70 basis points to 25.3%. The commercial s...
- Pro forma net sales grew 13% year-over-year to $924 million, driven by volume and price realization in both commercial and residential segments.
- Adjusted EBITDA increased 16% to $233 million, with margins expanding 70 basis points to 25.3% due to operating leverage and cost management.
- Commercial segment sales surged 24% (18% combined) to $610 million, with orders up 41% and backlog rising 124% to $2.5 billion.
- +7 more takeaways
Vestis Corporation Q2 2026 Earnings Call - Raised Full-Year EBITDA and Free Cash Flow Guidance Amid Transformation Progress
Vestis Corporation delivered a pivotal second quarter, marking its first year-over-year adjusted EBITDA growth in over two years and reversing a long-standing trend of declining operating leverage. Th...
- Adjusted EBITDA reached $74.5 million, a 19% year-over-year increase on a covenant-adjusted basis, marking the first YoY growth in over two years.
- Free cash flow guidance for fiscal 2026 was raised to $120 million-$150 million, up from the previous range of $50 million-$60 million.
- Full-year adjusted EBITDA guidance was increased to $295 million-$325 million, with a new midpoint of $310 million, up from the prior midpoint of $300 million.
- +7 more takeaways
Alliance Laundry Systems Q1 2026 Earnings Call - Raised Guidance on Strong Volume and Pricing Power
Alliance Laundry Systems delivered a robust first quarter, with revenue growing 10% year-over-year to $427 million. The growth was driven by a healthy mix of volume increases and disciplined pricing a...
- Revenue grew 10% year-over-year to $427 million, driven by a blend of 3% real volume growth and disciplined pricing actions.
- Adjusted EBITDA rose 9% to $109 million, with margins holding at 25.5% despite the incremental costs of operating as a public company.
- Management raised full-year guidance, now expecting 6-7% revenue growth and 7-8% adjusted EBITDA growth.
- +7 more takeaways
American Public Education Inc. Q1 2026 Earnings Call - Raised Guidance on Record Revenue and Margin Expansion
American Public Education (APEI) delivered a robust first quarter of 2026, reporting total revenue of $174.7 million, a 6.2% year-over-year increase that landed at the high end of management’s guidanc...
- Total revenue grew 6.2% year-over-year to $174.7 million, landing at the high end of guidance. Excluding the prior year’s Graduate School USA revenue, underlying revenue growth was 8.7%.
- Adjusted EBITDA surged 37.5% to $29.2 million, with the margin expanding 381 basis points to 16.7%, reflecting significant operating leverage and cost discipline.
- Diluted EPS increased 129% to $0.94, driven by higher net income and an unusually low 8% effective tax rate stemming from tax deductions related to stock appreciation.
- +10 more takeaways
Hims & Hers Health Q1 2026 Earnings Call - Strategic Pivot to Branded GLP-1s Drives Record Subscriber Growth and Raised Revenue Outlook
Hims & Hers Health delivered a Q1 2026 that was less about immediate profitability and more about a deliberate, high-stakes platform pivot. The company abruptly shifted its weight loss specialty from ...
- Q1 2026 revenue reached $608 million, up 4% year-over-year, while subscribers grew 9% to nearly 2.6 million.
- The company executed a major strategic pivot in March, discontinuing compounding GLP-1 advertising to prioritize branded Wegovy products through a Novo Nordisk partnership.
- The pivot generated $33 million in one-time restructuring costs, primarily from write-downs of the compounded GLP-1 supply chain, which compressed Q1 adjusted EBITDA margins.
- +9 more takeaways
Marathon Digital Holdings Q1 2026 Earnings Call - Strategic Pivot to AI Infrastructure Anchored by Long Ridge Acquisition and Starwood Joint Venture
Marathon Digital Holdings is executing a deliberate pivot from pure-play Bitcoin mining to a digital infrastructure company built on energy-backed compute. The strategy rests on three interconnected p...
- Strategic Pivot to Digital Infrastructure: MARA is transitioning from a pure-play Bitcoin miner to an energy-backed digital infrastructure company, leveraging its control over low-cost power to monetize AI and critical IT workloads across multiple tiers.
- Long Ridge Acquisition: The company announced a definitive agreement to acquire Long Ridge Energy & Power from FTAI Infrastructure, adding over 1 GW of potential capacity. The asset includes a highly efficient 505 MW combined-cycle gas turbine, 1,600 contiguous acres, and $144 million in annualized adjusted EBITDA, providing immediate cash flow and a premier compute campus in the PJM Interconnection.
- Starwood Joint Venture: MARA has moved from announcement to execution with Starwood, a capital-efficient partnership that allows the company to convert its powered land portfolio into equity stakes in large-scale AI data centers without significant incremental capital. The structure accelerates tenant acquisition and de-risks development through Starwood’s EPC and operational expertise.
- +7 more takeaways
Coherus Oncology Q1 2026 Earnings Call - LOQTORZI Sales Surge 61% as Pipeline Progresses Amidst Weather Disruption
Coherus Oncology delivered a strong Q1 2026 performance, driven by a 61% year-over-year increase in LOQTORZI net sales, which reached $11.8 million. Despite a 10% sequential decline attributed to seve...
- LOQTORZI Q1 2026 net sales rose 61% year-over-year to $11.8 million, though a 10% sequential decline from Q4 2025 was driven by severe winter storms disrupting patient treatment cycles.
- New patient starts for LOQTORZI reached an all-time high in Q1, with 75-80% of patients in metastatic settings and a growing focus on locally advanced recurrent cases.
- Management reaffirmed revenue guidance: $15 million per quarter in 2026, $30–35 million in 2027, and a peak of $44 million per quarter by 2028.
- +7 more takeaways